Advertisements

Aquasol-A

Quick links to important sections

Aquasol-A

Advertisements
Advertisements

Method of action: Wound Healing

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Aquasol-A

Aquasol-A is classified as a specialized dual-acting vitamin supplement and epithelial support agent preparation. Its identity is centered on providing foundational nutrient support by combining two essential active ingredients: Vitamin A and Dexpanthenol.

Property Description
Active ingredient Vitamin A (Retinol/Retinyl Palmitate) and Dexpanthenol
Form Parenteral Solution, Oral Capsule, Topical preparation
Pharmacological class Vitamin Supplement (Fat-Soluble & B-complex Precursor)
Common use Nutritional balance and epithelial maintenance
Origin Derived (synthetic analogue/ester)

What Type of Medicine is Aquasol-A? (Identity and Classification)

Aquasol-A belongs to the high-level pharmacological class of Vitamins, specifically bridging the essential categories of Fat-Soluble Vitamins and B-complex Vitamin Precursors. The preparation is established as a combination product containing the two core active components. A distinctive characteristic, particularly of the injectable and some oral forms, is its water-miscible or solubilized formulation. This technological feature is widely recognized in clinical settings to overcome the physiological barrier of poor fat absorption, ensuring the efficient delivery of the Vitamin A component even when fat digestion is compromised.


Active Ingredients and Composition (Vitamin A and Dexpanthenol)

The active ingredients are Vitamin A and Dexpanthenol. The Vitamin A component is frequently provided as Retinyl Palmitate, a stable ester that the body converts to active retinol. Dexpanthenol is a synthetic analogue and precursor to Pantothenic acid (Vitamin B5), a B-complex vitamin. This composition differentiates Aquasol-A from monotherapy Vitamin A supplements by providing simultaneous support. The preparation is classified as a derived product and is utilized in several high-level dosage forms, including a Parenteral Solution for injection and Oral Capsules.


What is the General Purpose of Aquasol-A? (High-Level Benefit)

The general purpose of Aquasol-A is to ensure essential nutrient replacement to restore the body’s fundamental nutritional balance. Vitamin A is an essential nutrient required for proper cell differentiation and epithelial maintenance, functions clinically recognized as crucial for the health of skin and mucous membranes. By providing the Dexpanthenol precursor, the preparation also helps support the synthesis of Coenzyme A, a molecule vital for numerous metabolic functions, thus contributing to overall cellular repair and growth. A typical use scenario involves providing necessary nutritional supplementation for patients diagnosed with malabsorption conditions.

Regulatory References

  1. DailyMed
Advertisements

What side effects are possible with Aquasol-A?

Possible Side Effects and Safety Information

The safety profile of Aquasol-A (Vitamin A and Dexpanthenol) is predominantly determined by the potential for Hypervitaminosis A (Vitamin A toxicity), a condition linked to the chronic and prolonged administration of high doses. Regulatory documents structure the risk profile by linking adverse reactions to the degree and duration of exposure.


Officially Documented Safety Concerns

Adverse reactions are classified by the affected organ system, primarily representing the consequences of Vitamin A overaccumulation:

  • Nervous System Disorders: Headache, drowsiness, and, in serious cases, manifestations of increased intracranial pressure (such as Pseudotumor Cerebri or papilledema).
  • Skin and Subcutaneous Tissue Disorders: Drying and cracking of the skin, alopecia (hair loss), and fissures of the lips.
  • Hepatobiliary Disorders: Hepatotoxicity (liver damage), jaundice, and hepatosplenomegaly are officially documented as serious adverse reactions.
  • General/Musculoskeletal: Fatigue, fever, irritability, bone and joint pain, and anorexia.

Serious Adverse Reactions and Restrictions

Serious adverse reactions listed in regulatory labeling include Hepatotoxicity and Pseudotumor Cerebri. Additionally, anaphylactic shock and death have been reported when the parenteral solution is administered via the intravenous route.

Population-Specific Safety Constraints mandate that use in excess of the recommended daily allowance is contraindicated in pregnant individuals due to the risk of teratogenicity (fetal abnormalities). The medicine is also contraindicated in patients with pre-existing Hypervitaminosis A.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Aquasol-A overdose is defined by the manifestation of Hypervitaminosis A Syndrome, resulting from the excess accumulation of its Vitamin A component. The official regulatory profile details specific clinical presentations and required emergency actions.

Documented Manifestations and Severe Outcomes

The syndrome presents with general signs including fatigue, malaise, anorexia, and vomiting. Specific clinical manifestations include headache, irritability, and severe dermatologic effects such as massive desquamation, alopecia, and fissuring of the lips. Severe outcomes explicitly documented in regulatory labeling involve hepatotoxicity (liver damage) and serious central nervous system effects, particularly increased intracranial pressure. This pressure is evidenced in infants by bulging fontanels. Skeletal effects in children include premature closure of the epiphysis. Diagnosis is supported by clinical presentation alongside laboratory findings such as a vitamin A plasma level over 1,200 Units/100 mL.

Emergency Action and Required Medical Help

The required official action upon identification of Hypervitaminosis A is the immediate withdrawal of the vitamin administration. This is followed by symptomatic and supportive treatment. Any suspected overdose or the presence of severe signs, such as those related to the CNS or liver, mandates seeking emergency medical attention to initiate the required care.

Advertisements

Therapeutic Uses of Aquasol-A

What Aquasol-A Treats: Main Uses and Benefits

Aquasol-A (Vitamin A Palmitate) may be part of symptomatic management, primarily for conditions characterized by periods of heightened symptoms related to deficiency. Its main use is commonly used to help with the treatment of vitamin A deficiency.

This medicine is applied across domains where additional symptomatic support is needed when oral administration is not feasible. Common clinical scenarios involve malabsorption syndrome with accompanying steatorrhea, or symptoms related to physical discomfort like anorexia, nausea, and vomiting.


The medicine helps address symptom clusters that may become intense or disruptive as a result of this nutritional imbalance. A brief listing of symptoms related to deficiency that the treatment may assist with includes night blindness and xerophthalmia (dry eyes). Vitamin A supports general well-being during symptomatic phases, including immune function and the integrity of the skin and mucous membranes.

“This application is relevant when supportive symptom management is appropriate.”

Therefore, receiving supportive relief contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability in systemic areas.

Quick Fact: Relevant for Easing Symptoms Related to Night Blindness

Regulatory References

  1. FDA-approved label via DailyMed
Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Aquasol-A

This information is based strictly on authoritative government regulatory documentation, such as FDA Prescribing Information, defining the populations eligible or non-eligible for this Vitamin A preparation.

Contraindicated Populations

Use of Aquasol-A is contraindicated (must not be used) in patients with the following conditions:

  • Hypervitaminosis A (pre-existing Vitamin A toxicity).
  • Hypersensitivity or known allergy to Vitamin A or any ingredient in the preparation.
  • Women who are or may become pregnant when the dose is in excess of the Recommended Dietary Allowance (RDA) of Vitamin A, due to established risk of fetal harm.
  • Administration via the Intravenous (IV) push route.

Restricted and Conditioned Use

  • Malabsorption Syndrome: The oral form is contraindicated in patients with malabsorption. The parenteral (intramuscular) route must be used instead for these patients.
  • Pregnancy and Lactation: Use during pregnancy is strictly limited to doses not exceeding the RDA and requires establishing clear need due to fetal risk associated with high doses (e.g., parenteral formulations are sometimes classified as Pregnancy Category X).
  • Age-Groups: The medicine is allowed for use across adults, infants, and children, but specific, differing dosage regimens are established for different age-groups.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe several clinically significant interactions for Vitamin A (the active component of Aquasol-A), primarily concerning changes in drug concentration and the risk of heightened toxicity.

Interactions with Increased Toxicity Risk

Co-administration with tetracycline antibiotics (e.g., demeclocycline, minocycline) may increase the risk of developing pseudotumor cerebri (intracranial hypertension). Concomitant use with other systemic oral retinoids (e.g., isotretinoin, acitretin) is restricted due to the potential for additive retinoid-related adverse effects (hypervitaminosis A).

Interactions Affecting Concentration

Certain medicines can affect the body's absorption or metabolism of Vitamin A. Mineral oil, some lipid-lowering drugs (e.g., cholestyramine), and neomycin may interfere with the gastrointestinal absorption of Vitamin A, potentially leading to lower levels. Conversely, oral contraceptives may result in increased plasma concentrations of Vitamin A. The regulatory label for Orlistat includes a requirement to separate its administration from Vitamin A by at least two hours to minimize absorption interference.

Interactions Affecting Co-administered Medicines

When high doses of Vitamin A are co-administered with anticoagulants (e.g., warfarin), the official profile notes a possible increased hypoprothrombinemic effect, which necessitates monitoring.

Advertisements

Mechanism of Action

Aquasol-A, a formulation of retinol (Vitamin A), is mobilized from hepatic stores bound to Retinol-Binding Protein 4 (RBP4), delivering it to extrahepatic target tissues. Inside the cell, retinol is sequentially oxidized, first reversibly to retinaldehyde by retinol dehydrogenases (RDH), and then irreversibly to the biologically active metabolite, all-trans-retinoic acid (ATRA), catalyzed by retinaldehyde dehydrogenases (RALDH).

ATRA functions as an agonist ligand for the Retinoic Acid Receptors (RARs) (alpha, beta, gamma), which form heterodimers with the Retinoid X Receptors (RXRs). This ligand-receptor complex binds to Retinoic Acid Response Elements (RAREs) in the promoter region of numerous target genes, leading to the recruitment of coactivators and the modulation of gene transcription. This downstream cascade regulates the expression of proteins involved in cellular proliferation, differentiation, and epithelial integrity. Separately, in the retina, retinol is converted to 11-cis-retinal, which binds to opsin to form rhodopsin, a photopigment essential for the transduction of light stimuli.

Advertisements

Dosage and Administration Information

How to use Aquasol-A: Official Administration Guidelines

Aquasol-A (Vitamin A Palmitate) is administered via two primary routes: intramuscular (IM) injection or oral forms (capsules/liquid), depending on the patient's condition and ability to absorb the vitamin.


Official Dosing and Administration Schedule

Age Group Route Initial Daily Dose Duration Follow-up Oral Therapy
Adults IM Injection 100,000 Units 3 days 10,000 to 20,000 Units daily for 2 months
IM Injection 50,000 Units 2 weeks (following initial 3 days)
Pediatric (1–8 yrs) IM Injection 17,500 to 35,000 Units 10 days 5,000 to 10,000 Units daily for 2 months
Infants IM Injection 7,500 to 15,000 Units 10 days 5,000 to 10,000 Units daily for 2 months
  • Intramuscular Administration: This route is indicated when oral intake is not feasible, such as in cases of malabsorption syndrome, vomiting, or pre/post-operative conditions. The injection must be given only into the muscle; intravenous (IV) administration is prohibited due to the risk of anaphylactic shock and death. The solution is a water-miscible preparation designed for IM use.
  • Oral Administration: Oral forms are used for maintenance or for the follow-up therapy recommended after the initial parenteral course. Oral capsules may be taken with or after food, as advised, with fatty foods generally enhancing absorption.

Procedural Rules

  1. Preparation: The parenteral solution is supplied as a Sterile single-dose vial (50,000 USP units/mL) for IM injection only. The injectable solution must be protected from light.
  2. Missed Dose (Oral): If a dose of the oral form is missed, take it as soon as remembered. If it is nearly time for the next scheduled dose, skip the missed dose. Do not take a double dose to make up for the missed one.
  3. Supervision: Prolonged daily dose administration exceeding 25,000 Units should be conducted under close professional supervision.

The full course of treatment requires an initial phase of high-dose IM injection (when necessary), followed by an oral therapeutic multivitamin preparation to ensure adequate liver stores of Vitamin A are achieved before concluding therapy.

Advertisements

Recent Clinical Evidence

Aquasol-A: Recent Clinical Evidence


Primary Clinical Trials: Efficacy and Outcomes

Research has examined the drug, which was investigated in studies. Trials have explored a change in symptoms in participants with active disease.

Key studies indicate that participants in the trials met the primary endpoint, which was pre-specified to measure disease activity. Research also evaluated the number of flare-ups over a 24-week period, a secondary endpoint of the trials.

The studies reported on participants' quality of life measures, which were assessed at 12 weeks. Additionally, studies monitored biological markers related to inflammation and disease progression.


Comparative Studies

Comparative research has explored the drug against an inactive control (placebo) and against traditional therapies. The findings were compared to outcomes observed with these existing treatments in the study. These comparisons help to contextualize the trial results.

Sub-studies evaluated whether combining this drug with other standard-of-care agents affected outcomes in a specific subset of participants who had not responded adequately to monotherapy. Participants in this research subset met the secondary endpoint for the combination therapy trial.


Long-Term Follow-up Data

Long-term follow-up studies extended up to five years, observing participants after the initial controlled trial period. Research explored the change in acute symptoms over time, and the long-term follow-up tracked the maintenance of the initial symptomatic change. Further research is ongoing to explore the drug compared to newer treatment options as they become available on the market.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Aquasol-A (FAQ)


Q: What are the most common signs of an allergic reaction to Aquasol-A?

A: Regulatory documents indicate that a severe allergic reaction, specifically an anaphylactoid type reaction, has been reported rarely, particularly following intramuscular or intravenous administration. This type of reaction is an emergency and involves signs that may affect the whole body. Patients who have a known hypersensitivity or allergy to Vitamin A or any ingredient in the preparation are designated as a contraindicated population in official information.

Q: If I miss a dose of Aquasol-A, what typically happens?

A: Official administration procedures describe the course of action for a missed oral dose as taking it when remembered, or skipping it if the next dose is due soon. The procedure specifies that a double dose to compensate for the missed one is generally avoided. The regulatory text does not provide a general statement about the physical consequence of missing a dose.

Q: Does taking Aquasol-A cause your skin to peel or dry out?

A: Yes, official adverse reaction documents list drying and cracking of the skin, as well as fissures of the lips, among the possible side effects, especially with high doses or prolonged use. These effects are manifestations of the vitamin’s activity on the skin and subcutaneous tissues.

Q: What is the difference between retinol and retinyl palmitate in Aquasol-A?

A: Aquasol-A provides the Vitamin A component as retinyl palmitate, which is a stable form of the vitamin. Retinyl palmitate is an ester that the body must convert into the biologically active form, retinol, once it is inside the body. This conversion process ensures the vitamin can perform its essential functions.

Q: How long does Aquasol-A stay in the body after stopping treatment?

A: The body primarily stores Vitamin A in the liver. Official information indicates that, once adequate liver stores are established, they are typically sufficient to satisfy the body's requirements for up to two years. This storage capacity is why treatment involves an initial phase to build up these reserves.

Q: Is it common for people to report stomach discomfort or nausea from Aquasol-A?

A: Official adverse reaction profiles related to high or prolonged doses include reports of gastrointestinal symptoms such as abdominal discomfort, nausea, and vomiting. The occurrence of these effects is typically information reviewed in consultation with a healthcare professional.

Q: Can long-term use of Aquasol-A affect my bone density?

A: The official safety profile links high-dose and prolonged use to potential issues in the musculoskeletal system, including bone and joint pain. The labeling also describes related skeletal issues, such as premature closure of the epiphysis (growth plate) in children.

Q: Can Aquasol-A cause weight gain or changes in appetite?

A: Official documents describe anorexia, which is a loss of appetite, as a general manifestation of Vitamin A overexposure (hypervitaminosis A). Information regarding weight gain is not listed in the standard adverse reaction profile for this drug.

Q: Does Aquasol-A interact with hormonal birth control pills?

A: Yes, official regulatory documents state that women who are taking oral contraceptives have been shown to have a significant increase in the plasma concentration (the amount measured in the blood) of Vitamin A. This is an important consideration reviewed during treatment.

Q: Is it normal to experience a headache after starting Aquasol-A?

A: Headache is listed in the official safety documents as a nervous system disorder and a possible manifestation of high levels of Vitamin A in the body. However, the regulatory text does not specify whether this is a common or expected symptom when starting a therapeutic dose.

Q: Does Aquasol-A contain any ingredients other than Vitamin A Palmitate?

A: Yes, Aquasol-A is a combination product that contains a second active ingredient, Dexpanthenol, a precursor to Vitamin B5. Furthermore, the parenteral (injection) form contains inactive ingredients such as chlorobutanol as a preservative, polysorbate 80, citric acid, and sodium hydroxide.

Q: Is Aquasol-A used for general nutritional deficiencies or just Vitamin A deficiency?

A: Aquasol-A is formally indicated for the treatment of Vitamin A deficiency. However, because it is a combination product that also contains Dexpanthenol, which supports Vitamin B5 pathways, its purpose is to address multiple foundational nutrient needs related to the deficiency.

Q: Does Aquasol-A have any known interactions with alcohol?

A: Official warnings describe that alcohol use should generally be avoided while taking Vitamin A supplements. This caution is in place because concurrent use may increase the risk of liver damage (hepatotoxicity).

Q: Can Aquasol-A be taken by people with diabetes or celiac disease?

A: The oral form is contraindicated in conditions leading to poor absorption from the gut, such as severe malabsorption syndromes, which may include celiac disease. In these cases, the injection (parenteral) form is used instead. Caution is generally advised for people with underlying medical conditions, and use is monitored.

Q: Does Aquasol-A affect my immune system function?

A: Official information from health bodies indicates that Vitamin A is an essential nutrient required for numerous bodily processes, including the proper growth and functioning of the immune system.

Q: Does the time of day I take Aquasol-A matter for its effectiveness?

A: Official administration instructions state that the oral form of the medication should be taken with or immediately after meals. Taking it near mealtime is important for ensuring proper absorption.

Q: What types of food are recommended to eat with Aquasol-A to help absorption?

A: Official administration guidelines note that the oral liquid form can be mixed with common foods and liquids to aid absorption, such as fruit juice, cereal, soft foods, formula, or breast-milk. Oral capsules are generally taken with food.

Q: Does Aquasol-A help with fertility or reproductive health?

A: Official sources describe Vitamin A as a necessary nutrient for the healthy growth and function of male and female reproductive organs. Deficiency in Vitamin A can impair these functions.

Q: Do people with certain existing health conditions need extra caution when taking Aquasol-A?

A: Yes, the official prescribing information advises that extra caution should be exercised when the medicine is used in certain patient groups. These include neonates with low birth weight and patients with pre-existing hepatic impairment (liver issues), requiring close professional supervision.

Q: Are there documented cases of severe side effects from Aquasol-A?

A: The regulatory label documents several severe adverse reactions associated with the medication. These include severe risks like Hepatotoxicity (liver damage), Pseudotumor Cerebri (increased pressure around the brain), and reports of anaphylactic shock when the injection is incorrectly administered intravenously.

Q: Is Aquasol-A a prescription-only medicine?

A: According to the official product information, the high-strength injection (parenteral) solution for Aquasol-A is classified as a Human Prescription Drug in the United States.

Q: How does the body store Vitamin A from Aquasol-A?

A: Official clinical pharmacology details state that the body stores most of its Vitamin A in the liver. Specifically, it is stored in specialized liver cells (Kupffer cells) mainly in the form of the palmitate ester, which is a highly storable form.

Q: Can Aquasol-A cause dizziness or vertigo?

A: The official safety profile includes reports of both dizziness and vertigo among the general manifestations associated with Vitamin A administration, particularly in instances of high dosage or hypervitaminosis A.

Q: Is Aquasol-A used to prevent measles complications?

A: In addition to treating deficiency, specific high-dose regimens of Vitamin A have been recognized and used in the management of children with measles, particularly in populations at high risk of deficiency, to help reduce the risk of complications.

Advertisements

How should Aquasol-A be stored and disposed of?

Storage and Disposal of Aquasol-A (Vitamin A Palmitate Injection)

The official labeling mandates specific environmental controls to maintain the product's stability.

Storage Requirements

The injectable solution requires storage under refrigeration, specifically between 2 C and 8 C (36 F to 46 F). It is explicitly required that the product Do not freeze. The medication must also be Protected from light. As a single-dose vial, any unused portion remaining after a quantity has been withdrawn must be discarded.

Disposal Instructions

All expired or unused medication should not be kept. For child safety, the product must be stored out of the reach of children.

Due to its form, used needles and syringes must be disposed of promptly in a puncture-resistant, dedicated container, following all local regulations for sharps and non-hazardous medical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aquasol-A found in:

A-Z Index: